Calamos Wealth Management LLC Increases Stake in Boston Scientific Corporation $BSX

Key Points

• Calamos Wealth Management LLC increased its stake in Boston Scientific Corporation by 2.9%, owning 101,786 shares valued at approximately $10.93 million as of the end of the second quarter.
• Boston Scientific posted strong quarterly earnings, with an EPS of $0.75, exceeding analyst expectations, and a revenue of $5.06 billion, marking a 22.8% year-over-year increase.
• Analysts remain optimistic about Boston Scientific's outlook, with several firms raising their price targets, suggesting a potential average target price of $120.71 for the stock.

Calamos Wealth Management LLC raised its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 2.9% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 101,786 shares of the medical equipment provider's stock after purchasing an additional 2,864 shares during the period. Calamos Wealth Management LLC's holdings in Boston Scientific were worth $10,933,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of BSX. Brighton Jones LLC raised its holdings in shares of Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after acquiring an additional 226 shares during the period. GAMMA Investing LLC raised its holdings in shares of Boston Scientific by 17.2% during the 1st quarter. GAMMA Investing LLC now owns 25,554 shares of the medical equipment provider's stock worth $2,578,000 after acquiring an additional 3,745 shares during the period. Envestnet Portfolio Solutions Inc. raised its holdings in shares of Boston Scientific by 10.9% during the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 66,857 shares of the medical equipment provider's stock worth $6,745,000 after acquiring an additional 6,551 shares during the period. Blue Trust Inc. raised its holdings in shares of Boston Scientific by 13.0% during the 1st quarter. Blue Trust Inc. now owns 5,000 shares of the medical equipment provider's stock worth $504,000 after acquiring an additional 575 shares during the period. Finally, Advisor Resource Council purchased a new position in shares of Boston Scientific during the 1st quarter worth $283,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $99.20 on Friday. Boston Scientific Corporation has a one year low of $80.64 and a one year high of $109.50. The company has a market cap of $146.99 billion, a PE ratio of 59.05, a P/E/G ratio of 2.39 and a beta of 0.61. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The business has a 50-day simple moving average of $101.29 and a 200-day simple moving average of $101.75.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the previous year, the company posted $0.62 earnings per share. The business's revenue for the quarter was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on BSX shares. Wells Fargo & Company lifted their price target on Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a report on Thursday, July 24th. BTIG Research boosted their price objective on shares of Boston Scientific from $127.00 to $132.00 and gave the company a "buy" rating in a report on Wednesday, October 1st. Needham & Company LLC reaffirmed a "buy" rating and set a $121.00 target price on shares of Boston Scientific in a research note on Friday. Robert W. Baird boosted their price target on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 1st. Finally, Oppenheimer upgraded shares of Boston Scientific from a "market perform" rating to an "outperform" rating and boosted their price target for the stock from $118.00 to $125.00 in a research note on Monday, September 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $120.71.

Insider Buying and Selling

In related news, EVP Arthur C. Butcher sold 17,313 shares of the company's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the transaction, the executive vice president directly owned 23,600 shares of the company's stock, valued at $2,469,268. This represents a 42.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $5,231,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares of the company's stock, valued at $18,659,923.46. This trade represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 174,214 shares of company stock valued at $17,972,457. Corporate insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.